pSivida Corp. (EYPT)

pSivida Corp. (EYPT) is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. pSivida Corp. (EYPT) is not very popular among insiders. pSivida Corp. (EYPT) is a mediocre stock to choose.
Log in to see more information.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and com...
EYPT Fundamental Data by TradingView

News

Analysts Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $30.63
Analysts Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $30.63

Zolmax Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned a consensus rating of "Buy" from the eight research firms that are currently covering the firm, Marketbeat...\n more…

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from Analysts
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from Analysts

Ticker Report Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been assigned an average rating of "Buy" from the eight ratings firms that are presently covering the firm, Marketbeat...\n more…

EyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded by StockNews.com to Sell
EyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded by StockNews.com to Sell

Ticker Report StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT - Free Report) to a sell rating in a research note released on Thursday. Other equities analysts have also recently issued...\n more…

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

Globe Newswire - Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU in wet AMD in 2024 -WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE...\n more…

Panagora Asset Management Inc. Boosts Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Panagora Asset Management Inc. Boosts Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Ticker Report Panagora Asset Management Inc. increased its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 205.5% in the 2nd quarter, according to the company in its most recent disclosure...\n more…

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

SeekingAlpha EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade...\n more…